Cargando…
Cryo-EM structures of PP2A:B55-FAM122A and PP2A:B55-ARPP19
Progression through the cell cycle is controlled by regulated and abrupt changes in phosphorylation.(1) Mitotic entry is initiated by increased phosphorylation of mitotic proteins, a process driven by kinases,(2) while mitotic exit is achieved by counteracting dephosphorylation, a process driven by...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491220/ https://www.ncbi.nlm.nih.gov/pubmed/37693408 http://dx.doi.org/10.1101/2023.08.31.555365 |
Sumario: | Progression through the cell cycle is controlled by regulated and abrupt changes in phosphorylation.(1) Mitotic entry is initiated by increased phosphorylation of mitotic proteins, a process driven by kinases,(2) while mitotic exit is achieved by counteracting dephosphorylation, a process driven by phosphatases, especially PP2A:B55.(3) While the role of kinases in mitotic entry is well-established, recent data have shown that mitosis is only successfully initiated when the counterbalancing phosphatases are also inhibited.(4) For PP2A:B55, inhibition is achieved by the two intrinsically disordered proteins (IDPs), ARPP19 (phosphorylation-dependent)(6,7) and FAM122A(5) (inhibition is phosphorylation-independent). Despite their critical roles in mitosis, the mechanisms by which they achieve PP2A:B55 inhibition is unknown. Here, we report the cryo-electron microscopy structures of PP2A:B55 bound to phosphorylated ARPP19 and FAM122A. Consistent with our complementary NMR spectroscopy studies both IDPs bind PP2A:B55, but do so in highly distinct manners, unexpectedly leveraging multiple distinct binding sites on B55. Our extensive structural, biophysical and biochemical data explain how substrates and inhibitors are recruited to PP2A:B55 and provides a molecular roadmap for the development of therapeutic interventions for PP2A:B55 related diseases. |
---|